Capricor Therapeutics (NASDAQ:CAPR) Trading Up 7.2% – Here’s Why

Capricor Therapeutics Inc (NASDAQ:CAPR)’s share price traded up 7.2% during trading on Wednesday . The company traded as high as $14.39 and last traded at $14.46. 377,074 shares were traded during trading, a decline of 52% from the average session volume of 787,141 shares. The stock had previously closed at $13.48.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. HC Wainwright reissued a “buy” rating and set a $77.00 price target on shares of Capricor Therapeutics in a report on Thursday, January 2nd. Cantor Fitzgerald raised their price target on Capricor Therapeutics from $25.00 to $30.00 and gave the company an “overweight” rating in a report on Thursday, November 14th. Finally, Piper Sandler began coverage on Capricor Therapeutics in a research note on Monday, October 21st. They issued an “overweight” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Stock Up 11.7 %

The company has a market cap of $684.69 million, a price-to-earnings ratio of -14.21 and a beta of 4.08. The company has a fifty day simple moving average of $14.06 and a two-hundred day simple moving average of $12.77.

Institutional Trading of Capricor Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CAPR. SG Americas Securities LLC purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth about $133,000. Oppenheimer & Co. Inc. lifted its stake in shares of Capricor Therapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 68,408 shares of the biotechnology company’s stock worth $1,040,000 after purchasing an additional 13,762 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics in the third quarter worth about $161,000. FMR LLC acquired a new stake in shares of Capricor Therapeutics in the third quarter valued at about $370,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Capricor Therapeutics by 868.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 17,699 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 15,872 shares during the period. Hedge funds and other institutional investors own 21.68% of the company’s stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.